Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984936 | 1.00 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL13866396 | 0.89 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL27324467 | 0.84 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL25306203 | 0.82 | PDE7A (0.46) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL11722126 | 0.81 | NPSR1 (0.55) | SMN1; SMN2MAPTHRH4MCHR1NPSR1 | |
| SCHEMBL12404063 | 0.81 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL12750774 | 0.81 | GAA (0.47) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL10156614 | 0.80 | MCHR1 (0.47) | HRH4MCHR1 | |
| SCHEMBL28778123 | 0.80 | MCHR1 (0.47) | HRH4MCHR1 | |
| SCHEMBL28387549 | 0.80 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188097-B2 | Pyrazolo[1,5-A]pyrimidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8188097-B2 | Pyrazolo[1,5-A]pyrimidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | MEN1 1656/4885KMT2A 2532/4885SMN1; SMN2 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.